Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 1998

View Archived Issues

Inex R&D pipeline update

Cellegy and 3M combine technologies

CoCensys initiates phase II migraine study with ganaxolone tablets

Orphan drug status granted to Endorex's ImmTher for Ewing's sarcoma

SciClone's lead cystic fibrosis drug found safe in phase I

Elan completes acquisition of Carnrick

Neuprex receives orphan drug designation for treatment of severe meningococcal disease

rAd-p53 in gene therapy of cancers with p53 mutation; overview of gene therapies in development

Schering-Plough acquires Canadian rights to Ribi's melanoma theraccine

VIMRx updates stockholders at annual meeting

Ventana Genetics reports novel method for identification of drug target sites

Melphalan derivative pinpointed for further study

Biovail granted license to Celgene's ADHD treatment

New class of FPTase inhibitors discovered at Merck & Co.

Astra prepares another series of immunomodulatory peptides

Tricyclic antitumor compounds developed at Schering-Plough

Modulators of drug/multidrug resistance from Lilly

RPR acquires worldwide rights to Novartis anticoagulant

Phase II trial with HGP-30W HIV vaccine begins in The Netherlands

Elan/Neurex merger nears completion

Antisense therapy for CMV retinitis receives priority review status from FDA

Roche reviews HIV product pipeline in time for AIDS conference

Amur's AM-454 blocks progression of type II diabetes in preclinical studies

Preclinical studies with doranidazole summarized

Two-year landmark study demonstrates importance of initiating triple therapy simultaneously

Pyrazoloacridine evaluated in patients with pancreatic and hepatobiliary cancer

Various schedules and doses of DMDC explored in phase I

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...